Glycomine
PrivateLast Round
Series C
Apr 16, 2025
Total Funding Raised
$228M
Company Overview
Glycomine operates in Healthcare & Life Sciences and is based in San Carlos, California. Its latest recorded funding round was a Series C round in April 2025.
Glycomine is a biopharmaceutical company that develops orphan drugs aimed at treating rare metabolic disorders and protein misfolding through innovative replacement therapies and targeted intracellular delivery systems.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Glycomine Comparables
Compare Glycomine with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Cycle Pharmaceuticals | 78% | |
| Maggie's Pearl, LLC | 77% | |
| Zydus Lifesciences | 76% |
For institutional investors. Book with your work email.
Glycomine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 16, 2025 | ||||
| Series B | Jun 23, 2021 | ||||
| Series B | Aug 7, 2019 | ||||
| Series A | Nov 16, 2016 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Glycomine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aberdeen Group plc | Series C |
| Asahi Kasei Therapeutics Venture Capital | Series B |
| Mesa Verde Venture Partners | Series A |
| CTI Life Sciences Fund | Series C |
| abrdn Inc. | Series C |
| Remiges Ventures | Series C, Series B |
| Advent Life Sciences | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 63% MoM, from 1.3K to 2.2K.
- Apr 16, 2025
$115M round raised
For institutional investors. Book with your work email.
Glycomine Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Glycomine's valuation, stock price, and market status.
Is Glycomine a public or private company?
Glycomine is a private company.
What is the current stock price of Glycomine?
Glycomine is a private company, so its shares have no public market price. Caplight tracks Glycomine's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Glycomine worth (valuation)?
Valuation information for Glycomine is not publicly available.
Can I buy Glycomine stock?
Glycomine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Glycomine's last funding round?
Glycomine's most recent funding round was Series C on April 16, 2025.
Who are the main investors in Glycomine?
Key investors in Glycomine include CTI Life Sciences Fund, abrdn Inc., Advent Life Sciences, Abingworth, Novo Holdings.
Will Glycomine IPO soon?
No public IPO plans have been announced for Glycomine.
How can I track Glycomine secondary market activity?
Caplight tracks bids, offers, and trades in Glycomine's shares on secondary markets.